Antibody persistence at 18-20months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China

Vaccine

Volumn 29, Issue 50, 2011, Pages 9337-9344

  Li, Rong Cheng ^a   Li, Feng Xiang ^b   Li, Yan Ping ^a   Hou, Qi Ming ^b   Li, Chang Gui ^b   Li, Ya Nan ^b   Chen, Fu Sheng ^c   Hu, Xue Zhong ^d   Su, Wen Bin ^e   Zhang, Shu Min ^b   Fang, Han Hua ^b   Ye, Qiang ^b   Zeng, Tian De ^c   Liu, Tao Xuan ^d   Li, Xiu Bi ^e   Huang, Yun Neng ^f   Deng, Man Ling ^f   Zhang, Yan Ping ^g   Ortiz, Esteban ^h  

^a Guanxi Autonomous Region Center for Disease Prevention   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c Ping Le County Center for Disease Prevention and Control   (China)

^d Li Pu County Center for Disease Prevention and Control   (China)

^e Yang Shuo County Center for Disease Prevention and Control   (China)

^f Gui Lin City Center for Disease Prevention and Control   (China)

^g Sanofi Pasteur ^*  (China)

^h SANOFI PASTEUR   (France)

Author keywords

Booster; China; Immunogenicity; Pediatric; Pentavalent vaccine; Safety

Indexed keywords

ACT HIB; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE PLUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE PLUS POLIOMYELITIS VACCINE; DIPLOID CELL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PENTAVAC; PENTAXIM; POLIOMYELITIS VACCINE; TETANUS ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ANOREXIA; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; CRYING; DIARRHEA; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEMORRHAGIC COLITIS; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; TONSILLITIS; TRACHEITIS; VACCINATION; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHINA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; POLIOVIRUS VACCINE, INACTIVATED; TETANUS TOXOID; VACCINES, COMBINED;

EID: 80855143743     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.131     Document Type: Article

References (53)

1. Edwards K.M., Decker M. Pertussis vaccines. Vaccines 2008, vol. 21:467-517. Saunders Co., Philadelphia, PA. 5th ed.
2. Hewlett E.L., Cherry J.D. New and improved vaccines against pertussis. New generation vaccines 1997, 387-416. Marcel Dekker Inc., New York, NY. 2nd ed. M.M. Levine, G.C. Woodrow, J.B. Kaper, G.S. Cobon (Eds.).
3. Cherry J. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997, 16(Suppl. 4):S90-S96.
4. Simondon F., Preziosi M.P., Yam A., Kane C.T., Chabirand L., Iteman I., et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997, 15:1606-1612.
5. WHO Pertussis vaccines. WHO position paper. Wkly Epidemiol Rec 2005, 80:29-40.
6. World Health Organization Expanded programme on immunization. Global advisory group. Part 1. Wkly Epidemiol Rec 1992, 67:11-15.
7. World Health Organization Global programme for vaccines and immunization (GPV): the WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 1998, 73:64-68.
8. World Health Organization WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec 2006, 81:445-452.
9. Decker M.D. Principles of pediatric combination vaccines and practical issues related to use in clinical practice. Pediatr Infect Dis J 2001, 20(11 Suppl.):S10-S18.
10. Kalies H., Grote V., Verstraeten T., Hessel L., Schmitt H.J., von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006, 25:507-512.
11. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care 2003, 9(1 Suppl.):S6-S12.
12. WHO vaccine preventable diseases: monitoring system 2011 global summary. Available from URL: [accessed 24.08.11]. http://www.who.int/vaccines/globalsummary/immunization/countryprofileselect.cfm.
13. Centers for Disease Control and Prevention (CDC) Certification of poliomyelitis eradication-Western Pacific Region, October 2000. MMWR Morb Mortal Wkly Rep 2001, 50(1):1-3.
14. Centers for Disease Control and Prevention (CDC) Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007, 56(38):996-1001.
15. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005, 59:587-635.
16. WHO. Vaccine-derived polioviruses-update Weekly Epidemiological Record (WER) 2006;81:397-408.
17. Heymann D.L., Sutter R.W., Aylward R.B. A global call for new polio vaccines. The end is near but eradication will not be as simple as once thought. Nature 2005, 434:699-700.
18. WHO Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 2006, 81(15):137-144.
19. WHO Global polio eradication initiative. Available at [accessed 24.08.11]. http://www.polioeradication.org/.
20. Yang Y., Leng Z., Lu D. Pediatric Haemophilus influenzae type b meninngitis in Hefei city: an epidemiologic study (Beijing Children's Hospital). Zhonghua Yi Xue Za Zhi 1998, 78(April (4)):251-253. [article in Chinese].
21. Yang Y., Leng Z., Shen X., Lu D., Jiang Z., Rao J., et al. Acute bacterial meningitis in children in Hefei, China 1990-1992 (Beijing Children's Hospital). Chin Med J (Engl) 1996, 109(5):385-388.
22. Levine O.S., Liu G., Garman R.L., Dowell S.F., Yu S., Yang Y.H. Haemophilus influenzae type b and Streptococcus pneumoniae as causes of pneumonia among children in Beijing, China. Respiratory Diseases Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892-7630, USA. Emerg Infect Dis 2000, 6(2):165-170.
23. Wang Y.J., Vuori-Holopainen E., Yang Y., Wang Y., Hu Y., Leboulleux D., et al. (Beijing Children's Hospital, China) Relative frequency of Haemophilus influenzae type b pneumonia in Chinese children as evidenced by serology. Pediatr Infect Dis J 2002, 21(4):271-277.
24. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000, 13:302-317.
25. Kalies H., Verstraeten T., Grote V., Meyer N., Siedler A., Schmitt H.J., et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004, 23(10):944-950.
26. Farhoudi D., Löfdahl M., Giesecke J. Invasive Haemophilus influenzae type b disease in Sweden 1997-2003: epidemiological trends and patterns in the post-vaccine era. Scand J Infect Dis 2005, 37(10):717-722.
27. Li R.C., Li F.X., Li Y.P., Hou Q.M., Li C.G., Li Y.N., et al. Immunogenicity and safety of a pentavalent acellular pertussis combined vaccine including diphtheria, tetanus, inactivated poliovirus and conjugated Haemophilus Influenzae type b polysaccharide for primary vaccination at 2, 3, 4 or 3, 4, 5 months of age in infants in China. Vaccine 2011, 29(10):1913-1920.
28. Plotkin S.A. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001, 20:63-75.
29. Capeding R.M., Cadorna-Carlos J., Book-Montellano M., Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine at 6, 10, 14 weeks of age (EPI schedule) and concomitant Hepatitis B vaccination at birth, 6, 14 or 6, 10, 14 weeks of age. WHO Bull 2008, 86:443-451.
30. Carlsson R.M., Claesson B.A., Selstam U., Fagerlund E., Granstrom M., Blondeau C., et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998, 17:1026-1033.
31. Carlsson R.M., Claesson B.A., Fagerlund U.E., Knutsson N., Laudin C. Antibody persistence in five-year old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002, 21:1535-1541.
32. Kanra G., Selier T., Yurdakök K., Yavuz T., Baskan S., Ulukol B., et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTacP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 2000, 18:947-954.
33. Lagos R., Kotloff K.L., Hoffenbach A., San Martin O., Abrego P., Ureta A.M., et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr Infect Dis J 1998, 17:294-304.
34. Mallet E., Fabre P., Pines E., Salomon H., Staub T., Schödel F., et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000, 19:1119-1127.
35. Thisyakorn U., Pancharoen C., Chuenkitmongkol S., Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Southeast Asian J Trop Med Public Health 2009, 40(March (2)):282-294.
36. WHO. United Nations prequalified vaccines (WHO list of vaccines for purchase by UN). [accessed 24.08.11]. http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html.
37. Eskola J., Ward J., Daga R., Goldblatt D., Zepp F., Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999, 354:2063-2068.
38. Mallet E., Matisse N., Mathieu N., Langue J., Boisnard F., Soubeyrand B. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004, March (22):1415-1422.
39. Langue J., Matisse N., Pacoret P., Undreiner F., Boisnard F., Soubeyrand B. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004, 22:1406-1414.
40. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5-7 years of age. Pediatrics 2006, 118(3):978-984.
41. Vidor E., Plotkin S.A. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin 2008, 4:328-340.
42. Olin P., Hallander H.O. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill 1999, 4:128-129.
43. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden. Appendix 2 to eleven-year report: person-time of follow-up and incidence calculations for Sanofi Pasteur vaccine specific cohorts. [accessed 24.08.11]. http://www.smittskyddsinstitutet.se/upload/Publikationer/11-y-report-app202-SPMSD.pdf.
44. Wang J., Yang Y., Li J., Mertsola J., Arvilommi H., Shen X., et al. Infantile pertussis rediscovered in China. Emerg Infect Dis 2002, 8(8):859-861.
45. Fung K.S., Yeung W.L., Wong T.W., So K.W., Cheng A.F. Pertussis-a re-emerging infection?. J Infect 2004, 48(2):145-148.
46. Sun M., Ma R., Zeng Y., Luo F., Zhang J., Hou W. Immunization status and risk factors of migrant children in densely populated areas of Beijing, China. Vaccine 2010, 28(5):1264-1274.
47. WHO The children's vaccine initiative and the global programme for vaccines and immunization. Recommendations from the special advisory group of experts. Part 1. Wkly Epidemiol Rec 1997, 72:237-243.
48. Johnson N.G., Ruggeberg J.U., Balfour G.F., Lee Y.C., Liddy H., Irving D., et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006, 12:937-941.
49. Fitzgerald M., Canny M., O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005, 10(39). E050929.2 [accessed 24.08.11]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2800.
50. Cruces R.P., Donoso F.A., Camacho A.J., Llorente H.M. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded program on immunization in Chile. Rev Chilena Infectol 2006, 23:50-54.
51. Cameron C., Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunization programme and changes to the meningitis C and Hib schedules. Euro Surveill 2006, 11(3). [accessed 24.08.11]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2913.
52. Cherry J.D., Brunell P.A., Golden G.S., Karzon D.T. Report of the task force on pertussis and pertussis immunization. Pediatrics 1988, 81:933-984.
53. Pichichero M.E., Deloria M.A., Rennels M.B., Anderson E.L., Edwards K.M., Decker M.D., et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997, 100:772-788.